EFDA Market Surveillance and Sampling of Medical Devices in Ethiopia

1. Key takeaways

After a marketing authorisation is granted, the device remains within EFDA’s market surveillance scope. The authority’s powers rest on Proclamation No. 1112/2019 and Council of Ministers Regulation No. 531/2023 (EFDA powers and duties), and surveillance follows a risk-based principle: sample products and regions are selected according to risk and leads, and testing may be performed by EFDA itself or entrusted to designated laboratories. For companies, sampling is therefore not a random variable: most of its triggers can be identified in advance. A product portfolio can be ranked by the same risk factors the authority is likely to apply, and preparation can be targeted at the products that rise to the top of that ranking rather than spread thinly across the entire catalogue. Treating surveillance as an unpredictable enforcement event, rather than as a foreseeable consequence of product and market characteristics, is the root cause of most poor outcomes when an inspector does arrive. The sections below map the legal basis of EFDA’s surveillance powers, the logic by which sampling targets are selected, and the preparation steps that keep a sampled product from turning into a compliance finding.

2. Legal basis

3. Expert insights

Insight 1: the legal basis of market surveillance is the authority’s general powers, not a device-specific chapter.

Unlike registration, changes and vigilance, the power to conduct market surveillance derives from EFDA’s general mandate as regulator (Proclamation No. 1112/2019 and Regulation No. 531/2023) rather than from a specific device provision. This gives surveillance actions considerable formal flexibility, and companies should not start any defence from the argument that the rule is not written down. The authority’s general enforcement powers are broad enough to support sampling, inspection and document demands across the product lifecycle.

Insight 2: risk-based selection means the sampling targets are calculated, not drawn at random.

A risk-based sampling logic typically weighs device risk class, past non-conformity records, the frequency of user reports, the sensitivity of storage and transport conditions, and whether the product category is prone to counterfeiting. On that basis, a company can run a self-ranking of its own portfolio and designate the high-scoring items as priority preparation targets (practical estimate: EFDA has not published a complete sampling scoring model; the factors above are a summary of common practice, and the specific criteria follow current official documents).

Insight 3: surveillance sampling and registration-stage laboratory testing are two separate mechanisms.

Laboratory testing at the registration stage corresponds to the 200 US dollars testing fee under Regulation No. 370/2015; surveillance sampling is initiated by the regulator. The initiating party, the sample source and the allocation of costs all differ between the two. Companies often assume that a product tested during registration will not be tested again, and are consequently left without retained samples or a retesting plan when a surveillance sample is drawn.

Insight 4: the port and the market are two separate surveillance surfaces.

At the port, what is verified is documentary consistency (a valid PO/PIP, the registration certificate, the CoC and the COO); in the market, what is verified is product consistency (whether the physical product matches the registration file, the label and the instructions for use). The same batch can clear the port smoothly and still be acted against in a market sample because the label or the performance does not match. Preparing for one surface therefore never substitutes for preparing for the other.

Insight 5: sampling results feed back into the marketing authorisation status.

Non-conformities found in sampling can trigger a field safety corrective action (FSCA), post-market change requirements, and even influence the assessment of the no-change confirmation at re-registration. This forms a closed loop of surveillance, vigilance and registration, and it is the reason surveillance findings should be routed into the same quality processes as vigilance events rather than handled as isolated inspection paperwork. The loop also works in the company’s favour: a documented history of clean samples and prompt responses becomes part of the risk picture that determines how often the product is selected in the first place.

4. Practical recommendations

1. Run a portfolio risk self-assessment: rank products by risk class, historical non-conformities, complaint frequency and storage-transport sensitivity to identify preparation priorities (practical estimate).
2. Establish a retained-sample system: keep sufficient retained samples per batch number to allow parallel retesting when a surveillance sample is drawn.
3. Keep the physical product consistent with the registration file: compare labels, instructions for use and model designations item by item, so that unreported changes are not exposed during sampling.
4. Prepare a technical response package: test reports, declaration of conformity, UMDN classification basis and key performance data, ready for rapid submission after sampling.
5. Route sampling results into vigilance and change processes: where a non-conformity appears, handle it jointly under the FSCA and change notification procedures.
6. Agree an on-site cooperation mechanism with the local representative: define who handles sampling, sample taking and document receipt, and how fast feedback is given.

5. Verification checklist

• □ Legal basis of EFDA market surveillance confirmed (Proclamation No. 1112/2019, Regulation No. 531/2023)
• □ Portfolio self-assessment completed by risk dimension (practical estimate)
• □ Retained-sample system established by batch number
• □ Physical labels and instructions for use consistent with the registration file
• □ Technical response package complete (test reports, DoC, UMDN basis)
• □ Sampling results linked into the FSCA and change processes
• □ On-site cooperation mechanism agreed with the local representative

Regulatory information verified as of 29 October 2026. The EFDA powers and post-market surveillance requirements listed in this article follow the current text of Proclamation No. 1112/2019, Regulation No. 531/2023 and Section 7.2 of EFDA-GDL-046; content for which no official original has been obtained, such as the sampling scoring model, is marked as a practical estimate.

• Local resource in Ethiopia: GRZAN assists manufacturers from the Chinese mainland and overseas in engaging the Ethiopian Food and Drug Authority (EFDA) on marketing authorisation (MA), Certificate of Competency (CoC) and import licence applications, including local representative structuring and agreement review, SRA reliance rationales, UMDN coding and classification, technical documentation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorisation applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles compliance arguments, labelling and instructions-for-use localisation (English), and vigilance reporting with field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.